antagonist
An antagonist is like a key that fits the lock but won't turn it — and while it sits there, no working key can get in. It binds the receptor but produces no activation of its own, and by occupying the site it blocks the natural messenger or an agonist drug.
In pharmacological terms an antagonist has affinity but no efficacy: it has zero intrinsic activity. On its own it usually does nothing visible, because it has no signal to switch off; its effect only shows when there is agonist activity to oppose. Antagonists are everywhere in medicine — naloxone reverses opioid overdose at mu receptors, atenolol blocks beta-1 adrenoceptors to slow the heart, and antihistamines block histamine receptors.
Antagonism comes in different mechanical flavours. Competitive antagonists compete for the same binding site and can be overcome by raising the agonist dose, while non-competitive antagonists cannot be out-competed in the same way. This distinction matters greatly in clinical dosing and in interpreting dose–response curves.
Naloxone, a competitive antagonist at opioid receptors, displaces morphine and rapidly reverses life-threatening respiratory depression in overdose.
Antagonist blocking an agonist's effect.
A pure antagonist is distinct from an inverse agonist: an antagonist merely silences the receptor's response to other ligands, whereas an inverse agonist actively pushes the receptor below its resting activity.